ExtendBio

Extend Biosciences is a clinical-stage biotechnology company focused on improving the pharmacokinetic properties of peptides and proteins. The company utilizes its proprietary D-VITAMER platform to conjugate therapeutic molecules to Vitamin D, leveraging the natural Vitamin D binding protein (DBP) to extend circulating half-life and improve bioavailability. Their lead program, EXT418, is a long-acting parathyroid hormone (PTH) analog being developed for the treatment of hypoparathyroidism. By enhancing the delivery and duration of action of biologics, Extend Biosciences aims to provide more effective and patient-friendly treatments for endocrine and metabolic disorders.